Correlation between achieving SALT 20 score and clinician- and patient-reported outcomes among patients diagnosed with alopecia areata in the US: An assessment from the TARGET-DERM AA registry.

Challenge

SALT 20—a clinically meaningful hair regrowth threshold—had not been validated against patient-reported outcomes in a real-world AA cohort, leaving uncertainty about whether achieving this threshold translates into improvements in patient-experienced disease burden across AA-specific and generic PRO instruments.

Solution

The TARGET-DERM AA registry was used to compare changes in CGI-AA, AAPPO, P-SAT, and PROMIS anxiety/depression scores between patients who achieved SALT 20 and those who did not, providing the first real-world validation of SALT 20 as a clinically meaningful PRO-anchored response threshold.

Impact

Demonstrating that SALT 20 achievement is associated with significant improvements across multiple clinician- and patient-reported AA outcomes provides the clinical meaningfulness evidence needed to justify SALT 20 as a regulatory endpoint in AA trials and supports AbbVie's label strategy for rinvoq and other JAK inhibitors.